Literature DB >> 29406243

Incorporation of a recombinant Eimeria maxima IMP1 antigen into nanoparticles confers protective immunity against E. Maxima challenge infection.

Mark C Jenkins1, Laura Stevens2, Celia O'Brien3, Carolyn Parker3, Katrzyna Miska4, Vjollca Konjufca2.   

Abstract

The purpose of this study was to determine if conjugating a recombinant Eimeria maxima protein, namely EmaxIMP1, into 20 nm polystyrene nanoparticles (NP) could improve the level of protective immunity against E. maxima challenge infection. Recombinant EmaxIMP1 was expressed in Escherichia coli as a poly-His fusion protein, purified by NiNTA chromatography, and conjugated to 20 nm polystyrene NP (NP-EmaxIMP1). NP-EMaxIMP1 or control non-recombinant (NP-NR) protein were delivered per os to newly-hatched broiler chicks with subsequent booster immunizations at 3 and 21 days of age. In battery cage studies (n = 4), chickens immunized with NP-EMaxIMP1 displayed complete protection as measured by weight gain (WG) against E. maxima challenge compared to chickens immunized with NP-NR. WG in the NP-EMaxIMP1-immunized groups was identical to WG in chickens that were not infected with E. maxima infected chickens. In floor pen studies (n = 2), chickens immunized with NP-EMaxIMP1 displayed partial protection as measured by WG against E. maxima challenge compared to chickens immunized with NP-NR. In order to understand the basis for immune stimulation, newly-hatched chicks were inoculated per os with NP-EMaxIMP1 or NP-NR protein, and the small intestine, bursa, and spleen, were examined for NP localization at 1 h and 6 h post-inoculation. Within 1 h, both NP-EMaxIMP1 and NP-NR were observed in all 3 tissues. An increase was observed in the level of NP-EmaxIMP1 and NP-NR in all tissues at 6 h post-inoculation. These data indicate that 20 nm NP-EmaxIMP1 or NP-NR reached deeper tissues within hours of oral inoculation and elicited complete to partial immunity against E. maxima challenge infection. Published by Elsevier Ltd.

Entities:  

Keywords:  Avian coccidiosis; Eimeria maxima; Nanoparticles; Recombinant antigen

Mesh:

Substances:

Year:  2018        PMID: 29406243     DOI: 10.1016/j.vaccine.2017.11.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Chlamydia-Specific IgA Secretion in the Female Reproductive Tract Induced via Per-Oral Immunization Confers Protection against Primary Chlamydia Challenge.

Authors:  Nita Shillova; Savannah E Howe; Besmir Hyseni; Deahneece Ridgell; Derek J Fisher; Vjollca Konjufca
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 2.  A review of Eimeria antigen identification for the development of novel anticoccidial vaccines.

Authors:  J Venkatas; M A Adeleke
Journal:  Parasitol Res       Date:  2019-05-08       Impact factor: 2.289

3.  Em14-3-3 delivered by PLGA and chitosan nanoparticles conferred improved protection in chicken against Eimeria maxima.

Authors:  Muhammad Haseeb; Jianmei Huang; Shakeel Ahmed Lakho; Zhang Yang; Muhammad Waqqas Hasan; Muhammad Ehsan; Muhammad Tahir Aleem; Muhammad Ali Memon; Haider Ali; Xiaokai Song; Ruofeng Yan; Lixin Xu; Xiangrui Li
Journal:  Parasitol Res       Date:  2022-01-05       Impact factor: 2.289

Review 4.  Coccidiosis: Recent Progress in Host Immunity and Alternatives to Antibiotic Strategies.

Authors:  Youngsub Lee; Mingmin Lu; Hyun S Lillehoj
Journal:  Vaccines (Basel)       Date:  2022-01-29

Review 5.  Vaccines against chicken coccidiosis with particular reference to previous decade: progress, challenges, and opportunities.

Authors:  Tean Zaheer; Rao Zahid Abbas; Muhammad Imran; Asghar Abbas; Ali Butt; Sarfraz Aslam; Jameel Ahmad
Journal:  Parasitol Res       Date:  2022-08-04       Impact factor: 2.383

6.  Protective Immunity Induced by an Eimeria tenella Whole Sporozoite Vaccine Elicits Specific B-Cell Antigens.

Authors:  Marco A Juárez-Estrada; Amanda Gayosso-Vázquez; Guillermo Tellez-Isaias; Rogelio A Alonso-Morales
Journal:  Animals (Basel)       Date:  2021-05-09       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.